Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Submits Tamiflu sNDA For Pediatric Capsules

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, children’s capsules would be manufactured in 30 mg and 45 mg doses; adult dose is 75 mg.

You may also be interested in...



Roche To Tailor Tamiflu Production As Supply Is Ample To Meet Demand

Supply of the antiviral significantly exceeds current orders for pandemic planning, Roche reports.

Roche To Tailor Tamiflu Production As Supply Is Ample To Meet Demand

Supply of the antiviral significantly exceeds current orders for pandemic planning, Roche reports.

Tamiflu U.S. Labeling Adopts Japanese Warnings

Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.

Topics

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel